|
*****REGISTER NOW ONLY 9 PLACES LEFT***** Enjoyed the crisp, relevant conference on Anti-bacterials”
Sudha Ravishanker, Research Scientist, AstraZeneca Antimicrobial resistance is continuously growing whilst the number of new drugs being developed and reaching the market are few, to say the least. Everyday, we hear news of new superbugs hitting the global community. This problem demands a fresh approach to combating resistance. So why does the pharmaceutical industry show so little interest in developing new antibiotics? |  |
SMi’s Superbugs & Superdrugs; A focus on antimicrobials will tackle the key issues in antimicrobial resistance. We will examine the complex procedures for getting drugs through regulatory hurdles taking into account the difference in requirements in the US and EU. Dive into the R&D pipeline and inspect the novel advances in drug development. Do not miss this opportunity to find out the incentives for development and learn of the advances in the pipeline for both anti-bacterials & anti-fungals. Hear international case studies and expert opinions from leaders in the field, including: - Dr Kenneth Tack, Executive Director, Pfizer
- Dr Tom P Gootz, Senior Research Fellow, Department of Antibiotics, Immunology and Cancer, Pfizer
- Dr Neil S Ryder, Executive Director, Infectious Diseases, Novartis Institutes for Biomedical Research
- Jeff Hermes, Senior Director Microbil Biochemistry, Merck Research Laboratories
- Dr PJ Turner, Associate Director, Infection Discovery, AstraZeneca
- Dr E David G McIntosh, Medical Director Infectious Diseases, Wyeth Europa
- Dr Ron Van Amsterdam, Senior Clinical Research Manager, Astellas Pharma Europe
- Dr Dieter Haebich, Director, Medicinal Chemistry, Bayer
- Soren Kjaerulff, Director, Antimicrobial Peptides, Molecular Biotechnology, R&D, Novozymes
- Dr Joyce Sutcliffe, Chief Research Scientist, Rib-X Pharmaceuticals
- Dr Nachum Kaplan, Vice President, Microbiology, Affinium Pharmaceuticals
- Nafsika Georgopapadakou, Vice President, Infectious Diseases, MethylGene
- Dr Lloyd Czaplewski, Director of Research, Prolysis Ltd
- Prof. Malcolm G. P. Page, Head of Biology, Basilea Pharmaceutica
- William Weiss, Director, Drug Evaluation, Cumbre Pharmaceuticals
- Dr Stephen Hawser, Director of Microbiology, Arpida
- John Powers, MD, National Institute of Health
- Mair Powell, Medical Assessor, Licensing Division, MHRA
Chaired by: Professor Ian Chopra, Professor of Microbiology, Institute of Molecular & Cellular Biology University of Leeds WHO SHOULD ATTEND SUPERBUGS & SUPERDRUGS? You should attend this conference if you are an Executive, Director, Chemist or Scientist working in the pharmaceutical or biotech industries within: - Microbiology
| - Antibiotics
| - Immunology
| - Infection Discovery
| - Infectious Diseases
| - Drug evaluation
| - Medicinal Chemistry
| - Molecular Biotechnology
| - Clinical Pharmacology
| - Drug Development
| - Drug Discovery
| - Project Management
| - New Product Development
| - Preclinical Development
| - Scientific Affairs
| - Portfolio Management
| - Licensing
| |
WHO WILL YOU MEET AT SUPERBUGS & SUPERDRUGS? A sample of the companies already in attendance includes: - Abingworth Management
| - Achaogen
| - Affinium Pharmaceuticals
| - Anacor Pharmaceuticals
| - Arpida
| - Astellas Pharma
| - AstraZeneca
| - Basilea Pharmaceutica
| - Bayer Healthcare
| - Bioniche Life Sciences
| - CRS Clinical Research Services Andernach
| - Cubist Pharmaceuticals
| - Cumbre
| - European Medicines Agency (E M E A)
| - GlaxoSmithKline
| - Merck
| - MethylGene
| - Mutabilis
| - Mutabilis
| - National Institute of Health
| - Novartis
| - Novozymes
| - Pfizer
| - Prolysis
| - Rib - X - Pharmaceuticals
| - Targanta Therapeutics
| - University Medical Centre Utrecht
| - Wood Mackenzie
| - Wyeth
| |
|
Events Home Page
